Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Edor Kabashi wins the International Medicine PG Award for Amyotrophic Lateral Sclerosis (ALS) research

Published on: 26/10/2016 Reading time: 1 min
Edor Kabashi
Retour à la recherche

The Paulo Gontijo Institute awarded the International Medicine PG Award to Edor Kabashi, team leader at the Brain and Spine Institute – Institut du Cerveau, for his research on the development of new models and new therapeutic avenues for Amyotrophic Lateral Sclerosis (ALS).

Edor Kabashi joined the Brain and Spine Institute - Institut du Cerveau - ICM in 2011 as the “Treatment of Amyotrophic lateral sclerosis: from genetics to zebrafish” team leader. He obtained his PhD in 2008 at McGill University and did postdoctoral work at Centre of Excellence in Neuromics at University of Montreal. He received many awards, including the Brain Star Award of CIHR Institute of Neuroscience in 2009 and 2011, and the Young investigator award from European Network for the Cure of ALS in 2015.

The International Medicine PG Award is an initiative of the Paulo Gontijo Institute to foster the research of young researchers around the world to promote the cure of ALS.

Selected from 15 studies, Kabashi’s studies have provided a breakthrough in developing new models and therapeutic avenues for Amyotrophic Lateral Sclerosis (ALS).

 

“My team works to better understand how a variety of genetic mutations can cause motor neuron degeneration in ALS. We take advantage of a simple vertebrate model, zebrafish where one or several genes can be manipulated. Using this paradigm, we have described that several major ALS genes interact together and function in common pathways and we are currently identifying drugs which could affect these molecular targets”, says Edor Kabashi.

 

The International Medicine PG Award is recognized by the international scientific community. Its partners the International Alliance of ALS, Motor Neuron Disease Association (MNDA) and the European Community for research for the cure of ALS (ENCALS). The study results will be presented at opening ceremony of the 26th International Symposium on ALS / MND (motor neuron disease) to be held in Dublin (Ireland) in December.

Our news on the subject

TDAH : les troubles de l’attention sont associées à l’intrusion d’ondes du sommeil pendant l’éveil
ADHD: Attention difficulties are linked to the intrusion of sleep waves during wakefulness
Attention-deficit/hyperactivity disorder (ADHD) remains poorly understood from a biological perspective. An international study led by scientists from the Paris Brain Institute and Monash University in Australia suggests that some symptoms may be...
03.17.2026 Research, science & health
L’IRM structurelle ne permet pas, à elle seule, de diagnostiquer la dépression
Structural MRI alone cannot diagnose depression
Can brain imaging reveal whether a person is affected by depression? This question has driven research for many years. Changes in brain structure have indeed been observed in patients with depression, suggesting that structural MRI might one day help...
03.12.2026 Research, science & health
Épilepsie temporale : une nouvelle stratégie pour corriger l’activité électrique anormale
Temporal Lobe Epilepsy: A New Strategy to Correct Abnormal Electrical Activity
Many patients suffer from epilepsy that cannot be controlled by current medications. Surgical removal of epileptogenic brain regions is effective in only about half of cases, and not all patients are eligible for the procedure. For these individuals...
03.06.2026 Research, science & health
Stimuler les mitochondries pour doper la mémoire à long terme
Stimulating Mitochondria to Boost Long-Term Memory
An international team led by Jaime de Juan-Sanz at the Paris Brain Institute has shown that slightly increasing the metabolic capacity of neurons can enhance long-term memory in both fruit flies and mice. The study, published in Nature Metabolism...
02.24.2026 Research, science & health
Traitements anti-Alzheimer
Anti-Alzheimer Treatments: A Long-Term Beneficial Effect on Symptoms
There is currently no cure for Alzheimer's disease. The treatments available in France—which are not reimbursed—are known as symptomatic treatments, meaning that they act on the consequences of the disease rather than its underlying cause. In 2018...
02.19.2026 Research, science & health
État de mal épileptique
Status Epilepticus: New Insights Gained from National Health Data
The most severe form of epilepsy, status epilepticus is a high-risk neurological emergency. Yet its epidemiology remains poorly understood, particularly in France. By analyzing data from the French National Health Insurance system, compiled within...
02.19.2026 Research, science & health
See all our news